Halofantrine

From Self-sufficiency
Revision as of 11:26, 20 September 2010 by Jontas (Talk | contribs) (1 revision)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Not to be confused with the Halfan culture.
Halofantrine
File:Halofantrine.svg
Systematic (IUPAC) name
3-dibutylamino-1-[1,3-dichloro-6-(trifluoromethyl)
phenanthren-9-yl]-propan-1-ol
Clinical data
Routes of
administration		 Oral
Pharmacokinetic data
Protein binding 60 to 70%
Metabolism Hepatic (CYP3A4-mediated)
Biological half-life 6 to 10 days
Identifiers
CAS Number 69756-53-2
ATC code P01BX01 (WHO)
PubChem CID 37393
DrugBank APRD00419
Chemical data
Formula C26H30Cl2F3NO
Molar mass 500.423 g/mol[[Script error: No such module "String".]]
  (verify)
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Halofantrine is a drug used to treat malaria. Halofantrine's structure contains a substituted phenanthrene, and is related to the antimalarial drugs quinine and lumefantrine. Marketed as Halfan, halofantrine is never used to prevent malaria and its mode of action is unknown. A crystallographic study have shown that halofantrine binds to hematin in vitro, suggesting a possible mechanism of action [1]. Alternatively or in addition, halofantrine has been shown to bind to plasmpesin, a haemoglobin degrading enzyme unique to the malarial parasites [2].

Adverse reactions

Halofantrine can cause abdominal pain, diarrhoea, vomiting, rash, headache, itching and elevated liver enzymes.

It can be associated with cardiotoxicity.[3] The most dangerous side effect is cardiac arrhythmias: halofantrine causes significant QT prolongation,[4] and this effect is seen even at standard doses. The drug should therefore not be given to patients with cardiac conduction defects and should not be combined with mefloquine. A survey from 2009 suggests that the drug is safe when correctly administered [5]

Pharmacology

The mechanism of action of halofantrine is unknown. The absorption of halofantrine is erratic, but is increased when taken with fatty food. Because of fears of toxicity due to increased halofantrine blood levels, halofantrine should be taken on an empty stomach.

Plasma levels peak at 16 hours and the half-life of the drug is about 4 days.

Uses

Halofantrine is only used to treat malaria. It is not used to prevent malaria (prophylaxis) because of the risk of toxicity and unreliable absorption.

Dosing

  • Adult dose: Three doses of 500 mg six hours apart.

Halofantrine should be taken on an empty stomach.

Manufacturing information and availability

  • Halfan (GlaxoSmithKline) is available as 250 mg tablets. A full treatment cost (6 tablets) costs US$1.40 in the developing world. Halofantrine is not available in the UK or U.S.

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />
Alveo-
late
Individual
agents
Other
Lumefantrine (combined with artemether as Coartem)
Halofantrine
DHFR inhibitors
(antifols)
Combination
Fansidar# (pyrimethamine-sulfadoxine)
Other
Atovaquone (always combined with proguanil as Malarone)
Tetracycline • Doxycycline#
Clindamycin
Combi-
nations
Fixed-dose (coformulated) ACTs
Coartem# • ASAQ (Coarsucam) • ASMQ •
Duo-Cotecxin (Artekin) • Pyramax
Combination therapies
(not co-formulated)
Quinine/tetracycline • Quinine/clindamycin •
Artequin • Ariplus • Co-Arinate • CDA
Hetero-
kont
50px This antiinfective drug article is a stub. You can help ssf by expanding it.
it:Alofantrina pl:Halofantryna
  1. ↑ de Villiers KA, Marques HM, Egan TJ (2008). "The crystal structure of halofantrine-ferriprotoporphyrin IX and the mechanism of action of arylmethanol antimalarials". J. Inorg. Chem. 102 (8): 1660–7. doi:10.1016/j.jinorgbio.2008.04.001. PMID 18508124. 
  2. ↑ Friedman R, Caflisch A (2009). "Discovery of plasmepsin inhibitors by fragment-based docking and consensus scoring". ChemMedChem. 4 (8): 1317–26. doi:10.1002/cmdc.200900078. PMID 19472268. 
  3. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  4. ↑ Sánchez-Chapula JA, Navarro-Polanco RA, Sanguinetti MC (2004). "Block of wild-type and inactivation-deficient human ether-a-go-go-related gene K+ channels by halofantrine". Naunyn Schmiedebergs Arch. Pharmacol. 370 (6): 484–91. doi:10.1007/s00210-004-0995-5. PMID 15558243. 
  5. ↑ Bouchaud O, Imbert P, Touze JE, Dodoo AN, Danis M, Legros F (2009). "Fatal cardiotoxicity related to halofantrine: a review based on a worldwide safety data base". Malaria J. 8: 289. doi:10.1186/1475-2875-8-289. PMC 2801676 Freely accessible. PMID 20003315. 
Retrieved from "http://ssf.f15ijp.com/wiki/index.php?title=Halofantrine&oldid=32611"